Introduction to Assessing Emerging Therapies For Melanoma Brain Metastases
Exploring Assessing Emerging Therapies For Melanoma Brain Metastases reveals several interesting facts. Zeynep Eroglu, MD, PhD, Moffitt
Assessing Emerging Therapies For Melanoma Brain Metastases Comprehensive Overview
Allison Betof Warner, MD, Stanford Event 4 of our Symposium Series. Listen to specialists Professor Richard Scolyer, A/Professor Alex Menzies and Professor Angela ... September 5, 2017: Lucia B. Jilaveanu, MD, PhD.
AIM at
Summary & Highlights for Assessing Emerging Therapies For Melanoma Brain Metastases
- Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the
- Panelists Jeffrey S. Weber, MD, PhD; Georgina Long, MD, PhD; Michael A. Davies, MD, PhD; Jason J. Luke, MD; and Robert H.I. ...
- While
- Allison Betof Warner, MD, Stanford University, Stanford, CA, describes the Phase II TrioMBM trial (NCT06712927) of triplet ...
- Zeynep Eroglu, MD, PhD, Moffitt
Stay tuned for more updates related to Assessing Emerging Therapies For Melanoma Brain Metastases.
